Browse by author
Lookup NU author(s): Dr Amardeep Khanna,
Professor David Jones
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© SAGE Publications. Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease. It has a varied course of progression ranging from being completely asymptomatic to aggressive disease leading to cirrhosis and resulting in liver transplantation. In addition, symptoms can be debilitating and can have a major impact on quality of life. For decades, there was only one anti-cholestatic agent available to target this disease and that was only effective in around half of patients, with little or no effect on symptoms. With increasing understanding of the pathogenic mechanisms of PBC and potential targets for drug treatment, pharmaceutical companies have shown a greater interest in this rare disease. A large number of novel therapeutic molecules have been developed and are currently being evaluated. In this review article all the novel molecules in use and in trials targeting cholestasis and symptoms in PBC are discussed.
Author(s): Khanna A, Jones DE
Publication type: Review
Publication status: Published
Journal: Therapeutic Advances in Gastroenterology
Print publication date: 01/10/2017
Online publication date: 07/09/2017
Acceptance date: 25/07/2017
ISSN (print): 1756-283X
ISSN (electronic): 1756-2848
Publisher: SAGE Publications Ltd